Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $7.49 in the prior trading day, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $7.59, up 1.34%. In other words, the price has increased by $1.34 from its previous closing price. On the day, 1.01 million shares were traded. AUPH stock price reached its highest trading level at $7.6052 during the session, while it also had its lowest trading level at $7.45.
Ratios:
Our goal is to gain a better understanding of AUPH by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.25. For the most recent quarter (mrq), Quick Ratio is recorded 5.26 and its Current Ratio is at 5.93. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.18.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 07 ’25 when Keenan Greg sold 8,305 shares for $8.23 per share. The transaction valued at 68,350 led to the insider holds 153,484 shares of the business.
Greenleaf Peter sold 195,593 shares of AUPH for $1,564,744 on Mar 03 ’25. The Chief Executive Officer now owns 1,953,892 shares after completing the transaction at $8.00 per share. On Mar 04 ’25, another insider, Greenleaf Peter, who serves as the Chief Executive Officer of the company, sold 164,947 shares for $7.92 each. As a result, the insider received 1,306,380 and left with 1,788,945 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1025439360 and an Enterprise Value of 909657408. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.48, and their Forward P/E ratio for the next fiscal year is 10.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.15 while its Price-to-Book (P/B) ratio in mrq is 2.99. Its current Enterprise Value per Revenue stands at 3.678 whereas that against EBITDA is 14.69.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.24, which has changed by 0.348135 over the last 52 weeks, in comparison to a change of 0.12677538 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $10.67, while it has fallen to a 52-week low of $5.20. The 50-Day Moving Average of the stock is -6.03%, while the 200-Day Moving Average is calculated to be -5.51%.
Shares Statistics:
The stock has traded on average 1.38M shares per day over the past 3-months and 2221380 shares per day over the last 10 days, according to various share statistics. A total of 137.75M shares are outstanding, with a floating share count of 119.37M. Insiders hold about 11.64% of the company’s shares, while institutions hold 45.00% stake in the company. Shares short for AUPH as of 1749772800 were 10530635 with a Short Ratio of 7.63, compared to 1747267200 on 10877775. Therefore, it implies a Short% of Shares Outstanding of 10530635 and a Short% of Float of 8.520000399999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
